Tempus AI, Inc. (TEM)

NASDAQ: TEM · Real-Time Price · USD
73.78
+2.19 (3.06%)
At close: Aug 15, 2025, 4:00 PM
73.53
-0.25 (-0.34%)
After-hours: Aug 15, 2025, 7:59 PM EDT
3.06%
Market Cap12.82B
Revenue (ttm)951.98M
Net Income (ttm)-199.73M
Shares Out 173.73M
EPS (ttm)-1.18
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume14,684,765
Open71.95
Previous Close71.59
Day's Range70.19 - 75.73
52-Week Range31.36 - 91.45
Betan/a
AnalystsBuy
Price Target65.36 (-11.41%)
Earnings DateAug 8, 2025

About TEM

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharma... [Read more]

Sector Healthcare
IPO Date Jun 14, 2024
Employees 2,400
Stock Exchange NASDAQ
Ticker Symbol TEM
Full Company Profile

Financial Performance

In 2024, Tempus AI's revenue was $693.40 million, an increase of 30.38% compared to the previous year's $531.82 million. Losses were -$746.33 million, 180.6% more than in 2023.

Financial numbers in USD Financial Statements

Analyst Summary

According to 12 analysts, the average rating for TEM stock is "Buy." The 12-month stock price target is $65.36, which is a decrease of -11.41% from the latest price.

Price Target
$65.36
(-11.41% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade

Ark Invest CEO Cathie Wood is known for her stock picks over the last decade, handpicking many of the growth stocks that find their way into the company's ETFs.

1 day ago - Benzinga

Tempus AI Stock: Is It A Buy Following Guidance Raise?

Tempus AI delivered strong revenue growth and beat expectations on both revenue and profit, but remains unprofitable at this stage. Sequential improvements in both revenue and loss per share highlight...

3 days ago - Seeking Alpha

TEM Investors Have Opportunity to Join Tempus AI, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , Aug. 12, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tempus AI, Inc. ("Te...

3 days ago - PRNewsWire

Tempus AI: Buy or Sell TEM Stock At $65?

Tempus AI stock has increased by 10% over the past week, fueled by impressive quarterly results and a raised sales forecast for the entire year. The company is now predicting an 82% year-over-year inc...

4 days ago - Forbes

Tempus AI, Inc. (TEM) Q2 2025 Earnings Call Transcript

Tempus AI, Inc. (NASDAQ:TEM) Q2 2025 Earnings Conference Call August 8, 2025 8:00 PM ET Company Participants Elizabeth Krutoholow - Vice President of Investor Relations & Competitive Intelligence Eri...

7 days ago - Seeking Alpha

TEM Earnings Rally: A.I. Use in Health Care, Drug Discovery

George Congdon joins Morning Movers to look at an AI player in the healthcare space: Tempus AI (TEM). Shares of TEM have rallied higher after its 2Q earnings.

7 days ago - Schwab Network

Tempus Reports Second Quarter 2025 Results

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...

7 days ago - Business Wire

Tempus AI Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Tempus AI, Inc. TEM will release earnings results for the second quarter before the opening bell on Friday, Aug. 8.

7 days ago - Benzinga

Tempus AI: Next Leg Up

Tempus AI is appealing after a 10% pullback, seeing it as an opportunity following strong Q1 results and a short report-driven dip. The precision medicine company should top Q2 estimates, especially w...

15 days ago - Seeking Alpha

Tempus AI: Data‑Driven Margin Lift, But Cash Burn Extends My Hold Stance

Tempus AI continues strong revenue growth, driven by its high-margin Data and Services segment and recent Ambry acquisition, but profitability remains elusive. Operational progress is evident, with ex...

16 days ago - Seeking Alpha

Tempus AI: Sustaining Growth Momentum With Acquisitions & Partnerships

I am strongly bullish on Tempus AI due to its strategic partnerships, Ambry Genetics acquisition, and leadership in AI-driven precision oncology. Tempus' collaborations and acquisitions position it at...

17 days ago - Seeking Alpha

Tempus to Report Second Quarter 2025 Financial Results on August 8

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter of 2025 o...

24 days ago - Business Wire

Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearanc...

4 weeks ago - Business Wire

Apple Acquisition Buzz: Its $60 Billion War Chest Is Enough To Buy Datadog And Tempus

Apple Inc's AAPL massive $60+ billion cash pile is once again in the spotlight – and with rivals racing ahead in AI, investors are wondering: is it finally time for Apple to make a bold move?

Other symbols: AAPLDDOG
5 weeks ago - Benzinga

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication,...

Other symbols: PSNL
5 weeks ago - Business Wire

Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care pathw...

5 weeks ago - Business Wire

Tempus AI: High-Growth And High-Risk

Tempus AI offers a compelling vision in precision oncology, boasting strong data assets, strategic partnerships, and rapid revenue growth. Valuation is rich, and execution risk is high—success depends...

6 weeks ago - Seeking Alpha

Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $650 ...

6 weeks ago - Business Wire

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer,...

6 weeks ago - Business Wire

Ambry Genetics' CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) company and a leader in clinical genomic testing, announced today that a peer-revie...

7 weeks ago - Business Wire

Tempus AI Is Well Worth Its Price Tag

Tempus AI's innovation in genomics, data, and applications makes the company well positioned to become a contender in the AI healthcare space. Strong innovation is clearly translating into their finan...

7 weeks ago - Seeking Alpha

Tempus to Participate in TD Cowen's 4th Annual Tools/Dx Revolution Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in TD Cowen's/Securities' 4th ...

2 months ago - Business Wire

Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Tempus AI, Inc. and Sets a Lead Plaintiff Deadline of August 12, 2025

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Shamis & Gentile, P.A: To: All persons or entities who purchased or otherwise acquired Tempus AI, Inc. (“Tempus” or ...

2 months ago - GlobeNewsWire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tempus AI, Inc. (TEM) and Encourages Shareholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDA...

2 months ago - Accesswire

Tempus Announces Collaboration with Northwestern University's Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer's Disease Research

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with The Abrams...

2 months ago - Business Wire